Revalesio Corp — SEC Form D Filing
Revalesio Corp filed an SEC Form D on December 16, 2025, reporting $38.88M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- December 16, 2025
- Amount reported
- $38.88M
- Round stage
- Series B+
- Industry
- Pharmaceuticals
- Website
- https://revalesio.com
Problem
Patients suffering from acute ischemic stroke and other neurological conditions currently have few therapeutic treatment options, leading to significant disability and reduced quality of life.
Solution
Revalesio develops a new class of drugs, exemplified by its lead candidate RNS60, which utilizes proprietary physics-based technology to address fundamental disease mechanisms and improve recovery in stroke and slow disease progression in chronic neurological conditions.
Why now
Revalesio is being started at this moment due to a regulatory shift, specifically the FDA's recent Fast Track Designation for RNS60, which accelerates the development and review of treatments for serious conditions with unmet medical needs like acute ischemic stroke.
Source: SEC EDGAR Form D filing